EUVIMEDEUVIMED entdecken
Open Access

In situ CAR-M engineered by liposomal mRNA nanomedicine remodels fibrotic microenvironment for ameliorating liver fibrosis

Hong Xiao iD, Xiaoxia Li iD, Kaimin Cai, Yifei Leng, Xiaoyan Miao iD, Tinghui Yin iD, Xintao Shuai iD, Jie Ren iD

Science Advances · 2026

DOI: 10.1126/sciadv.aeh6590 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Hong Xiao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Ultrasound, Laboratory of Novel Optoacoustic (Ultrasonic) Imaging, The Third Affiliated Hospital of Sun Yat-sen University, Gua…. Hauptthemen laut MEDLINE: Liver Cirrhosis, Liposomes, RNA, Messenger, Macrophages. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province, the fifth Five-Year Project of the Third Affiliated Hospital of Sun Yat-Sen University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Liver fibrosis is a severe complication of diverse chronic liver diseases characterized by a dysregulated hepatic microenvironment, and effective clinical therapeutic strategies for this condition remain lacking to date. Chimeric antigen receptor macrophages (CAR-Ms) hold considerable therapeutic potential for liver fibrosis via antigen-specific recognition and efferocytotic activity, yet their clinical translation is largely hindered by the sophisticated ex vivo preparation procedures. Herein, we report an in situ CAR-M engineering strategy that uses a phosphatidylserine (PS)–incorporated, macrophage-targeted lipid nanoparticle (LNP) for the codelivery of CAR messenger RNA (mRNA) and Cas9 mRNA in vivo. Our findings demonstrate that this engineered LNP achieves efficient targeting of liver-resident macrophages. Transfection with fibroblast activation protein α (FAPα)–CAR mRNA equips macrophages with the capacity to specifically target activated hepatic stellate cells (aHSCs), whereas Cas9-mediated follistatin-like protein 1 (FSTL-1) gene editing enhances the efferocytotic function of macrophages in liver tissues. Consequently, functional CAR-Ms are generated in situ, which elicits robust antifibrotic effects, including reduced collagen deposition, restored sinusoidal architecture and enhanced immune-mediated antifibrotic activity. Collectively, our customized LNP-mediated in situ engineering of liver macrophages into CAR-Ms enables precise antifibrotic intervention for liver fibrosis and circumvents the cumbersome ex vivo CAR-M preparation process.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver CirrhosisLiposomesRNA, MessengerMacrophagesNanomedicineCellular MicroenvironmentAnimalsMiceHepatic Stellate CellsHumansNanoparticles

Substanzen

LiposomesRNA, Messenger

Autor:innen und Institutionen

  • Department of Medical Ultrasound, Laboratory of Novel Optoacoustic (Ultrasonic) Imaging, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
  • Nanomedicine Research Center, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
  • PCFM Lab of Ministry of Education, School of Materials Science and Engineering, Sun Yat-sen University, Guangzhou 510275, China.

ORCID-Profile: Hong Xiao, Xiaoxia Li, Xiaoyan Miao, Tinghui Yin, Xintao Shuai, Jie Ren

Förderung

  • National Natural Science Foundation of China
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • the fifth Five-Year Project of the Third Affiliated Hospital of Sun Yat-Sen University
  • the Municipal Schools (Institutes) Joint Funding Project Basic Research Programme encompasses the Municipal Key Laboratory Construction Project
  • Hong Xiao the China International Medical Foundation

Zitieren

APA

Xiao, H., Li, X., Cai, K., Leng, Y., Miao, X., Yin, T., Shuai, X., & Ren, J. (2026). In situ CAR-M engineered by liposomal mRNA nanomedicine remodels fibrotic microenvironment for ameliorating liver fibrosis. Science Advances. https://doi.org/10.1126/sciadv.aeh6590

Vancouver

Xiao H, Li X, Cai K, Leng Y, Miao X, Yin T, et al. In situ CAR-M engineered by liposomal mRNA nanomedicine remodels fibrotic microenvironment for ameliorating liver fibrosis. Science Advances. 2026. doi:10.1126/sciadv.aeh6590

BibTeX
@article{Xiao2026,
  author = {Xiao, Hong and Li, Xiaoxia and Cai, Kaimin and Leng, Yifei and Miao, Xiaoyan and Yin, Tinghui and Shuai, Xintao and Ren, Jie},
  title = {In situ CAR-M engineered by liposomal mRNA nanomedicine remodels fibrotic microenvironment for ameliorating liver fibrosis},
  journal = {Science Advances},
  year = {2026},
  doi = {10.1126/sciadv.aeh6590}
}
Kostenlos starten →